Good
Partially Aligned
Patient Risk:
Medium
Summary
Core safety concepts requested by the provided label excerpts (embryo-fetal toxicity/teratogenicity and increased venous thromboembolism risk) are supported. Other claims made are not fully substantiated by the excerpts provided (e.g., detailed REMS/pregnancy-prevention program language, clinician-management phrasing, and “by country/product” listing).
Category Scores
Accurate Statements
Thalidomide is strongly associated with birth defects.
Supported by label excerpt 5.1: “powerful human teratogen… high frequency of severe and life-threatening birth defects, even after a single dose.”
Thalidomide can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy.
Supported by label excerpt 8.1: “THALOMID can cause embryo-fetal harm… and is contraindicated during pregnancy.”
Thalidomide is tightly controlled to prevent pregnancy exposure.
Supported by label excerpts 5.1 and 5.2: “THALOMID is only available through the THALOMID REMS program” and “females of reproductive potential may be treated… provided adequate precautions are taken to avoid pregnancy.”
The risk profile of thalidomide requires it to be prescribed and managed by a qualified clinician.
Partially supported by excerpt 5.3 advising patient/physician observance and immediate medical care; however, the label excerpt does not explicitly state “qualified clinician” wording.
Common safety considerations include avoiding use during pregnancy.
Supported by label excerpt 8.1: contraindicated during pregnancy; also consistent with 5.1 precautions to avoid pregnancy.
The use of THALOMID in patients with multiple myeloma results in an increased risk of venous thromboembolism (e.g., deep venous thrombosis and pulmonary embolism), especially with dexamethasone.
Supported by label excerpt 5.3 and supporting trial rate in 5.3; adverse reaction support in 6.1 includes deep vein thrombosis higher in THALOMID/dexamethasone arm.
Unsupported Statements
Thalidomide is used for the treatment of erythema nodosum leprosum (ENL).
No ENL indication text was provided in the supplied label excerpts (only multiple myeloma indication 1.1 was shown).
ENL is described as a painful inflammatory complication of leprosy.
No label excerpt defining ENL was provided.
In ENL, thalidomide helps control severe inflammatory episodes linked to leprosy.
No ENL indication/clinical benefit language was provided in the supplied label excerpts.
In multiple myeloma, the use of thalidomide depends on the treatment plan and other drugs given alongside it.
The excerpt shows increased VTE risk when combined with dexamethasone, but it does not support the broader claim about “depends on the treatment plan and other drugs” beyond the combination context shown.
The prescribing information (drug label) lists thalidomide’s approved indications by country and specific product.
No label text addressing country/product-specific indication listings was provided.
Thalidomide is used for the treatment of multiple myeloma, a cancer of plasma cells.
No label excerpt states “cancer of plasma cells” (clinical description). Label excerpt 1.1 supports multiple myeloma indication but does not include the plasma-cell descriptor.
Contradictions
Important Omissions
Boxed warning/REMS program operational details (e.g., specific pregnancy testing/contraception requirements, prescriber responsibilities) beyond general REMS availability and “adequate precautions.”
Importance:
Moderate
Specific dosing, administration, and thromboprophylaxis details (e.g., which prophylaxis to use, when to initiate, or specific monitoring steps).
Importance:
Moderate
Full boxed warning content and any other contraindications beyond pregnancy (e.g., other contraindications not provided in the excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several high-risk, safety-relevant concepts (teratogenicity/contraindication in pregnancy; increased VTE risk) are supported, but other claims lack substantiation from the provided excerpts and key REMS/monitoring/prophylaxis operational details are not evidenced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Some claims (especially ENL-related and certain label-structural statements) are not supported by the provided label excerpts; and key REMS/prescriber/monitoring details are not evidenced.
Suggested Improvement
Limit claims to label-supported excerpts (e.g., multiple myeloma indication 1.1; embryo-fetal toxicity 5.1/8.1; REMS availability and avoid pregnancy precautions 5.1/5.2; VTE risk 5.3 and adverse reaction 6.1). Provide and cite the specific label text for ENL indications and any detailed REMS/boxed warning requirements.